INSIGHTS UNLOCKED:
Featuring a discussion between Mr Gavin Lamb, Mr Ravi Barod and Mr Gren Oades
Prescribing Information (United Kingdom) [External link]
In this 12-minute video, a panel of experienced urologists discuss the potential benefits of adjuvant treatment in adults with RCC at increased risk of recurrence, emphasise the importance of ongoing collaboration across the MDT, and explore how they would introduce this treatment option to patients.
This video covers the following topics:
00:18 –
Panel introductions
00:53 –
How has the RCC treatment landscape changed throughout your career?
02:43 –
How do you prepare patients for their treatment journey and manage hesitations?
05:36 –
How has the availability of adjuvant treatment impacted your conversations with patients?
08:02 –
How can we optimise the combination of urology and oncology to support patients in their decision-making?
09:50 –
From your experiences, what key learning would you share with other urologists?
The expert panel
Mr Gavin Lamb
Urological Surgeon,
Forth Valley Hospital
Mr Ravi Barod
Consultant Urological
Surgeon, Royal Free Hospital
Mr Gren Oades
Consultant Urologist,
Queen Elizabeth Hospital
KEYTRUDA® (pembrolizumab) as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see the Summary of Product Characteristics).1
Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk associated with KEYTRUDA.
Interested in learning more about adjuvant
KEYTRUDA® (pembrolizumab) in renal cell carcinoma?
Abbreviations
emc, electronic medicines compendium; MDT, multidisciplinary team; PI, prescribing information; RCC, renal cell carcinoma.
Reference
- KEYTRUDA® (pembrolizumab) Summary of Product Characteristics. United Kingdom. Available at: https://www.medicines.org.uk/emc/product/2498. Accessed: March 2025.
Supporting documentation
Prescribing Information (United Kingdom) [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
